Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$138,411 Mln
P/E Ratio
74.86
P/B Ratio
6.36
Industry P/E
--
Debt to Equity
0.49
ROE
0.09 %
ROCE
6.05 %
Div. Yield
0 %
Book Value
14.64
EPS
1.25
CFO
$13,820.00 Mln
EBITDA
$22,128.00 Mln
Net Profit
$10,042.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Boston Scientific Corp (BSX)
| 13.23 | 0.45 | -0.49 | 46.60 | 32.07 | 22.68 | 18.57 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P 100
| -9.19 | -3.92 | -11.69 | 9.95 | 10.72 | 15.43 | 11.06 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Boston Scientific Corp (BSX)
| 53.96 | 24.94 | 8.92 | 18.16 | -20.50 | 27.96 | 42.28 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 130.09 | 225,270.82 | 17 | 31.07 | |
| 195.94 | 133,667.64 | 34.96 | 7.57 | |
| 507.57 | 167,787.35 | 72.95 | 15.62 | |
| 422.02 | 161,377.88 | 25.5 | 13.16 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and... treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. Address: 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 Read more
Chairman, President & CEO
Mr. Michael F. Mahoney
Chairman, President & CEO
Mr. Michael F. Mahoney
Headquarters
Marlborough, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Boston Scientific Corp (BSX) stood at $ 39,395 Mln as on 31-Dec-24
The share price of Boston Scientific Corp (BSX) is $101.14 (NYSE) as of 24-Apr-2025 12:33 EDT. Boston Scientific Corp (BSX) has given a return of 32.07% in the last 3 years.
Boston Scientific Corp (BSX) has a market capitalisation of $ 138,411 Mln as on 22-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/E ratio of Boston Scientific Corp (BSX) is 74.86 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Boston Scientific Corp (BSX) and enter the required number of quantities and click on buy to purchase the shares of Boston Scientific Corp (BSX).
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. Address: 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
The CEO & director of Mr. Michael F. Mahoney. is Boston Scientific Corp (BSX), and CFO & Sr. VP is Mr. Michael F. Mahoney.
There is no promoter pledging in Boston Scientific Corp (BSX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
22,494
|
|
|
17,245
|
|
|
16,488
|
|
|
13,641
|
| Boston Scientific Corp (BSX) | Ratios |
|---|---|
|
Return on equity(%)
|
9.03
|
|
Operating margin(%)
|
15.45
|
|
Net Margin(%)
|
11.06
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Boston Scientific Corp (BSX) was $1,853 Mln.
$2.22
(
